Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer.

ABSTRACT:

SUBMITTER: Palafox M 

PROVIDER: S-EPMC9663725 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature